



# ADA 2026: Clarivate's top takeaways in mainland China

Market Event Summary

Hardik Patel | June 2026

# Ecnoglutide's success over semaglutide in obese patients

## Background and study design

- Ecnoglutide (Sciwind Biosciences' Xianweiyang), a cAMP-biased GLP-1 receptor agonist, is a National Medical Products Administration (NMPA) approved therapy for adult type 2 diabetes (January 2026) and chronic weight management (March 2026) in mainland China.
- SLIMMER-UP-SWITCH is a Phase 2 comparison study of ecnoglutide and semaglutide in Chinese adult patients with obesity. The study is evaluating the percentage change in body weight relative to baseline.
- The study, initiated in July 2025, randomized 163 patients to receive either once-weekly SC ecnoglutide injection or once-weekly SC semaglutide.

## Top-line results

- Sciwind Biosciences presented interim analysis data at ADA 2026, demonstrating that ecnoglutide resulted in greater weight loss and a greater reduction in waist circumference than semaglutide SC at Week 20.

Outcome at Week 20	Ecnoglutide (cohorts in a 1:1 ratio)	Semaglutide SC (cohorts in a 1:1 ratio)
Percentage change in body weight	-12.80%	-9.50%
Waist circumference reduction	10.5 cm	8.7 cm

## Clarivate's takeaways



### Impact on uptake

Based on the ADA 2026 data, ecnoglutide demonstrated ~35% greater weight loss than semaglutide SC. This efficacy profile will enhance physician confidence, support broader adoption, and drive stronger market uptake.



### Strategic partnership

In February 2026, Sciwind announced a commercialization collaboration with Pfizer, strengthening ecnoglutide's competitive edge through Pfizer's global expertise and enabling Pfizer to directly enter the Chinese market, accelerating access and market penetration.



### Label expansion

With a Phase 3 trial ongoing for obstructive sleep apnea (OSA) and a Phase 1 trial for diabetic nephropathy, ecnoglutide is well-positioned to become a comprehensive metabolic powerhouse in the mainland China market upon receiving the respective label expansions.



### Growth constraints

Despite strong head-to-head performance versus semaglutide SC, fierce competition from existing GLP-1-based analogs, including tirzepatide (Eli Lilly's Mounjaro) and mazdutide (Innovent's Xinermei), will significantly exert downward pressure on the drug's market share and limit its growth potential.

# Ribupatide's dual-formulation advantage

## Background and study design

- Hengrui Pharma's ribupatide (HRS-9531), a dual GIP / GLP-1 RA, is an investigational therapy being co-developed with Kailera Therapeutics as a once-weekly SC injection and a once-daily oral pill.
- [HRS9531-T-201](#) is a Phase 2 trial to assess the safety and efficacy of once-daily oral ribupatide in adults with obesity (BMI  $\geq$  28 kg/m<sup>2</sup>) and without type 2 diabetes.
- The study includes 166 patients randomized in an equal ratio to receive once-daily oral ribupatide (10 mg, 25 mg and 50 mg) or placebo to assess the percentage change in body weight from baseline.

## Top-line results

- Hengrui Pharma and Kailera Therapeutics presented ribupatide clinical data at ADA 2026, demonstrating the drug's potential as a differentiated oral treatment option for people with obesity.

Endpoint (Week 26)	Ribupatide Oral	Placebo
Mean weight loss (efficacy estimand)	6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg) from baseline	2.3%
Mean weight loss (policy estimand)	6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg) from baseline	2.1%

## Clarivate's takeaways



### Metabolic breakthrough

Hengrui Pharma, which holds the commercialization rights for the drug in mainland China, filed an NDA with the NMPA for ribupatide for obesity and overweight and is evaluating the drug across multiple indications, including T2D (Phase 3), OSA with obesity (Phase 3), and two separate Phase 2 studies in patients with heart failure and PCOS co-morbid with obesity. This broad indication strategy strengthens the drug's systemic therapeutic value and supports its positioning as a comprehensive metabolic treatment.



### Dual-formulation advantage

By successfully advancing once-weekly SC injection and once-daily oral formulations, Hengrui Pharma is likely to position itself as a key player in the metabolic space. This multi-route franchise strategy allows the developers to capture distinct market segments, targeting needle-averse patients and early clinical interventions while maximizing market share.



### Overall drug uptake

We anticipate strong patient uptake for ribupatide upon market approval, supported by robust Phase 2 oral data demonstrating ~12% mean weight loss at 26 weeks. Notably, efficacy peaked and stabilized at the 25 mg dose, offering clear clinical advantages for early dose optimization. If competitively priced, the product could carve out a meaningful niche in the obesity market and gain an edge over established therapies, such as tirzepatide and semaglutide.

# About the author



## Hardik Patel, B.Tech.

### Healthcare Research & Data Analyst

#### DRG Commercial Solutions

Hardik Patel, B.Tech., is a healthcare research & data analyst on the China In-Depth team. He is involved in primary and secondary market research to create syndicated landscape and forecast content and provide market insights into various therapy areas in China, such as oncology and immunology. He has expertise in market sizing, market forecasting, competitive intelligence, and conducting primary market research across multiple disease areas. He holds a bachelor's degree in biotechnology from Lovely Professional University, Jalandhar, India.

### Clarivate coverage of the China market in 2026

- Alzheimer's Disease
- Asthma
- Atopic Dermatitis
- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- Crohn's Disease
- Gastroesophageal Cancer
- Hepatitis B Virus
- Migraine
- Myasthenia Gravis
- Non-Small-Cell Lung Cancer
- Obesity
- Prostate Cancer
- Squamous Cell Carcinoma of the Head and Neck



# Think forward™

**Have a question?**

[lsh.support@clarivate.com](mailto:lsh.support@clarivate.com)  
[clarivate.com](https://clarivate.com)

+1 215 386 0100 (U.S.)

+44 (0) 20 7433 4000 (Europe)

#### **About Clarivate**

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit [clarivate.com](https://clarivate.com).

**© 2026 Clarivate. All rights reserved**

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.